Conceptio › Archive › HAL (France)
HAL (France)open access

In vitro screening of compounds for targeting gastric cancer with Y220C p53 mutation: a molecule combining zinc chelation and a Michael acceptor drives CDKN1 and BBC3 expression to restore a p53-dependent cytotoxicity.

Simon Nannini et al.
HAL (France) · Papers · License: Open Access
Open Source ↗
gastriccancerp53targetedtherapy
Metal chelation s NaNNiNi, 1, P53, Covalent drugs, Targeted therapy, 0, Gastric cancer
This document is indexed with metadata only — full text is not available in the archive for this record. Open the official source ↗
Record · ID 226932
Retrieved via Conceptio — every document is proof-bundled with source, license, and retrieval metadata.